Delivery Order SPE2DB22D2206-SPE2DB25FJH43
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,729.22 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count supply). This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 1, 2025, and represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical supply relationships with the federal government. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $8,784.72 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. No set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $11,783.17 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $3,186.89 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (30-count packages). The contract is firm fixed price with no set-aside designation and was awarded on August 13, 2025, with an ultimate completion date of August 14, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count) with a ceiling value of $3,977.47. This contract represents a firm fixed-price delivery order under a competitive, non-set-aside procurement and is scheduled for completion by July 25, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office and serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units) under a firm fixed-price contract valued at $8,276.16. The award was made on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $34,374.97 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count units) on August 5, 2025, with completion targeted for August 6, 2025. This firm fixed price, non-set-aside contract represents a routine pharmaceutical procurement executed under competitive procedures. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical supplier for federal...
- The Defense Logistics Agency awarded a $3,853.29 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for Myrbetriq ER 50 mg tablets (90-count supply). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 12, 2025. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, and represents a child delivery order under a larger contract vehicle. This delivery...
- The Defense Logistics Agency awarded a $25,044.82 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Myrbetriq ER 50 mg tablets (90-count units). This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $29,045.67 to AmerisourceBergen Drug Corp for Myrbetriq ER 50 mg tablets (90-count supply) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a primary...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJH43Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,851.48 to AmerisourceBergen Drug Corp for the supply of Myrbetriq ER 50 mg tablets (90-count units). This firm fixed-price, non-set-aside delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, leverages this prime IDC to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare programs worldwide. The company's contract portfolio with the Defense Logistics Agency demonstrates extensive experience fulfilling federal medical supply requirements across multiple therapeutic domains, positioning it as a key pharmaceutical supplier for defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.9k | 8/8/25 |